期刊
INTERNATIONAL JOURNAL OF CANCER
卷 134, 期 3, 页码 596-605出版社
WILEY
DOI: 10.1002/ijc.28390
关键词
MSI; CHFR; colorectal cancer; methylation; taxanes; gemcitabine
类别
资金
- MDxHealth
Phenotypic differences among cancers with the same origin may be associated with chemotherapy response. CHFR silencing associated with DNA methylation has been suggested to be predictive of taxane sensitivity in diverse tumor types. However, the use of microsatellite instability (MSI:unstable-MSS:stable) as a predictive marker for therapeutic effect has had conflicting results. We examined these molecular alterations as predictors of chemotherapy sensitivity in colorectal cancer (CRC). Differential sensitivity to docetaxel and gemcitabine was compared to potential predictive biomarkers CHFR methylation and MSI status. Cell lines that were MSI-H/CHFR-methylated, MSS/CHFR-methylated and MSS/CHFR-unmethylated were assessed for in vivo sensitivity of CRC cell line xenografts to docetaxel and/or gemcitabine. We observed increased sensitivity in vitro to gemcitabine in cell lines with MSI and docetaxel in cell lines with CHFR inactivation via DNA methylation. In vivo treatment of human xenografts confirmed differential sensitivity, with the MSI-H/CHFR-methylated line RKO having tumor growth inhibition to each agent, and at least additive tumor growth inhibition with combination therapy. The MSS-CHFR-unmethylated line, CACO(2), was resistant to single and combination therapy, while COLO205, the MSS/CHFR-methylated line, showed tumor growth inhibition with docetaxel, but not gemcitabine, therapy. CHFR methylation in CRC cell lines predicted for sensitivity in vitro and in vivo to docetaxel, while MSI-H cell lines were more sensitive to gemcitabine. These data suggest that a subset of CRC patients would be selectively sensitive to a novel combination of gemcitabine and docetaxel, and are the basis for an ongoing clinical trial of this combination in a biomarker-selected patient population. What's new? A key molecular feature of colorectal cancer is microsatellite instability (MSI), which in sporadic disease is associated with hypermethylation, a phenomenon that in some instances appears to improve sensitivity to chemotherapy. The authors of this study, who previously found that methylation of CHFR, a regulator of cell division, is correlated with MSI phenotype, report here that CHFR methylation is predictive of docetaxel sensitivity, while MSI status is predictive of gemcitabine sensitivity. The findings suggest that colorectal cancer patients with both MSI and CHFR methylation may benefit from combined docetaxel and gemcitabine therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据